EU Statement – UN General Assembly 3rd Committee: Interactive dialogue on persons affected by leprosy

Thank you, Chair.

I have the honor to deliver this statement on behalf of the European Union and its Member States. We thank the Special Rapporteur for her report, which highlights the persistent challenges in accessing medicines and treatment for persons affected by leprosy, and reaffirms that this remains a key human rights issue.

Madam Special Rapporteur,

The Sustainable Development Goals, particularly Goals 3 and 10, aim to promote health and equality for all. We share your view that the exclusion of leprosy from universal health coverage undermines these Goals, perpetuating discrimination and inequality instead of effectively addressing these issues.

We note with concern that persons affected by leprosy in various countries, particularly those facing conflict, political instability or the impacts of climate change, have reported recurring delays in access to medication, as also highlighted in your report. The consequences of such delays can be irreversible and sometimes fatal, affecting not only those living with leprosy but also their families and communities.

Madam Special Rapporteur, 

As most countries where leprosy is endemic rely on WHO coordination for access to medicines, could you share your thoughts on engagement with WHO in ensuring that these countries can better forecast, procure and track medicines independently?

As repeated shortages undermine trust in public health systems, leading to reduced care-seeking and weakened disease control efforts, could you share some best practices on your engagement with medicines and treatment producers?

Thank you.